home
partners
contact

Uitgaven
partners
Vacatures
Nieuws
Agenda
Opleidingen
Adverteren
Redactie

home > Uitgaven > Radionuclide therapieën in Nederland: zijn we er klaar voor?

Radionuclide therapieën in Nederland: zijn we er klaar voor?

Beschouwing

Auteur

L. van Golen, A. Braat, B. de Keizer, C. Leijen, Prof. M. Lam

Vakblad

TvNG

Editie

2021-02, juni

^{De PDF wordt automatisch gedownload. Afhankelijk van uw browser of device opent deze zich automatisch of staat in de downloads van uw browser}

Inhoudsopgave

The volume of radionuclide therapies is expanding fast. It is gaining more popularity. Especially [¹⁷⁷Lu]Lu-PSMA therapies are expected to increase rapidly when positive results of the VISION trial will be published. As the prevalence of prostate carcinoma is high, the expected volume of requested therapies - after approval by EMA - are huge and needs the attention of medical staff of nuclear medicine departments. Special focus on production capacity of radionuclide therapies, therapeutic and diagnostic facilities, training of medical doctors, dosimetry guided therapy planning and radiation protection is needed. With this overview we hope to give insight in the expected increase of requested therapies and accompanied challenges on the short and long term.

Hoofdpartner

Business partners

Copyright
Algemene voorwaarden
Disclaimer
Privacy
Sitemap
Colofon

© Kloosterhof Neer BV